Cambridge, UK, May 2021: o2h Ventures are excited to announce that Small Pharma backed by the fund managers “o2h human health EIS fund” has completed a fund raise of $58M CAD and listed on the Toronto Stock Exchange.

Sunil Shah, CEO at o2h Ventures said: “This is a very exciting event for Small Pharma and they now have raised the funds required to see them through the next phase of the development of their drug.  Congratulations to Peter Rands and the team at Small Pharma for this tremendous event”.  

Small Pharma will use the funds to accelerate the development of effective therapeutic treatments for mental health disorders and will trade on the Canadian TSX Ventures Exchange (TSXV). 

About o2h Ventures

The o2h human health Fund was the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information about o2h Ventures Funds, please visit 

Media Contact:

Ajit Singh, Marketing Manager,

About Small Pharma 

Small Pharma is a neuropharmaceutical company specialised in IP led development of novel treatments for mental health condition, with a focus on depression. Small Pharma initiated a clinical program into N, N-dimethyltryptamine (“DMT”) assisted therapy in February 2021.  This program includes a Phase I/IIa trial on their lead candidate alongside development of a robust pipeline of proprietary preclinical assets.

For further information contact:

Peter Rands, Chief Executive Officer